שוודיה - שוודית - Läkemedelsverket (Medical Products Agency)

roche ab - midazolamhydroklorid - injektionsvätska, lösning - 5 mg/ml - midazolamhydroklorid 5,56 mg aktiv substans - midazolam

שוודיה - שוודית - Läkemedelsverket (Medical Products Agency)

roche ab - ribavirin - filmdragerad tablett - 200 mg - natriumlaurilsulfat hjälpämne; ribavirin 200 mg aktiv substans; cetylalkohol hjälpämne - ribavirin

שוודיה - שוודית - Läkemedelsverket (Medical Products Agency)

roche ab - ribavirin - filmdragerad tablett - 400 mg - ribavirin 400 mg aktiv substans - ribavirin

שוודיה - שוודית - Läkemedelsverket (Medical Products Agency)

roche ab - valganciklovirhydroklorid - filmdragerad tablett - 450 mg - valganciklovirhydroklorid 496,3 mg aktiv substans - valganciklovir

שוודיה - שוודית - Läkemedelsverket (Medical Products Agency)

roche ab - ceftriaxonnatrium (hemiheptahydrat); lidokainhydrokloridmonohydrat - pulver och vätska till injektionsvätska, lösning - 1 g - ceftriaxonnatrium (hemiheptahydrat) 1,19 g aktiv substans; lidokainhydrokloridmonohydrat 37,34 mg aktiv substans - kombinationer

שוודיה - שוודית - Läkemedelsverket (Medical Products Agency)

roche ab - benserazidhydroklorid; levodopa - tablett - 100 mg/25 mg - benserazidhydroklorid 28,5 mg aktiv substans; levodopa 100 mg aktiv substans; mannitol hjälpämne - levodopa och dekarboxylashämmare

שוודיה - שוודית - Läkemedelsverket (Medical Products Agency)

roche ab - benserazidhydroklorid; levodopa - depotkapsel, hård - 100 mg/25 mg - levodopa 100 mg aktiv substans; mannitol hjälpämne; benserazidhydroklorid 28,5 mg aktiv substans - levodopa och dekarboxylashämmare

שוודיה - שוודית - Läkemedelsverket (Medical Products Agency)

roche ab - benserazidhydroklorid; levodopa - dispergerbar tablett - 100 mg/25 mg - benserazidhydroklorid 28,5 mg aktiv substans; levodopa 100 mg aktiv substans - levodopa och dekarboxylashämmare

שוודיה - שוודית - Läkemedelsverket (Medical Products Agency)

roche ab - benserazidhydroklorid; levodopa - dispergerbar tablett - 50 mg/12,5 mg - levodopa 50 mg aktiv substans; benserazidhydroklorid 14,25 mg aktiv substans - levodopa och dekarboxylashämmare

האיחוד האירופי - שוודית - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastiska medel - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq som monoterapi är indicerat för behandling av vuxna patienter med lokalt avancerad eller metastaserad icke-småcellig lungcancer efter tidigare kemoterapi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq som monoterapi är indicerat för behandling av vuxna patienter med lokalt avancerad eller metastaserad icke-småcellig lungcancer efter tidigare kemoterapi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.